Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021)
Beam Therapeutics (BEAM) reported Long-Term Investments of $24.5 million for Q3 2021, down 16.62% on a QoQ basis from $29.4 million in Q2 2021.
Beam Therapeutics (BEAM) has 2 years of Long-Term Investments data on file, last reported at $24.5 million in Q3 2021.
- Quarterly Long-Term Investments changed N/A year-over-year to $24.5 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $24.5 million (changed N/A YoY) and the FY2020 annual result came in at $2.6 million, changed N/A from the prior year.
- Long-Term Investments eased to $24.5 million in Q3 2021 per BEAM's latest filing, from $29.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $29.4 million in Q2 2021 and bottomed at $2.6 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 24.54 Mn |
| Jun 30, 2021 | 29.43 Mn |
| Dec 31, 2020 | 2.58 Mn |